TWI752961B - 經雜芳基取代之吡啶及使用方法 - Google Patents

經雜芳基取代之吡啶及使用方法 Download PDF

Info

Publication number
TWI752961B
TWI752961B TW106118418A TW106118418A TWI752961B TW I752961 B TWI752961 B TW I752961B TW 106118418 A TW106118418 A TW 106118418A TW 106118418 A TW106118418 A TW 106118418A TW I752961 B TWI752961 B TW I752961B
Authority
TW
Taiwan
Prior art keywords
amino
dihydro
sulfonyl
phenyl
carbonyl
Prior art date
Application number
TW106118418A
Other languages
English (en)
Chinese (zh)
Other versions
TW201802085A (zh
Inventor
羅伯 J 歐登巴克
安卓 伯丹
朱維尼 皮卓 都尼蘇 寇提
馬爾龍 Ｄ 寇瓦特
史蒂芬 N 葛斯樂
漢斯 柯特曼
菲利浦 Ｒ 肯
德 普拉斯 史蒂芬 艾蜜勒 凡
王學慶
Original Assignee
盧森堡商艾伯維公司
比利時商葛萊伯格有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 盧森堡商艾伯維公司, 比利時商葛萊伯格有限公司 filed Critical 盧森堡商艾伯維公司
Publication of TW201802085A publication Critical patent/TW201802085A/zh
Application granted granted Critical
Publication of TWI752961B publication Critical patent/TWI752961B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106118418A 2016-06-03 2017-06-03 經雜芳基取代之吡啶及使用方法 TWI752961B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345315P 2016-06-03 2016-06-03
US62/345,315 2016-06-03

Publications (2)

Publication Number Publication Date
TW201802085A TW201802085A (zh) 2018-01-16
TWI752961B true TWI752961B (zh) 2022-01-21

Family

ID=59014678

Family Applications (4)

Application Number Title Priority Date Filing Date
TW106118418A TWI752961B (zh) 2016-06-03 2017-06-03 經雜芳基取代之吡啶及使用方法
TW112108367A TWI849782B (zh) 2016-06-03 2017-06-03 經雜芳基取代之吡啶及使用方法
TW110149319A TWI797926B (zh) 2016-06-03 2017-06-03 經雜芳基取代之吡啶及使用方法
TW113122971A TW202515560A (zh) 2016-06-03 2017-06-03 經雜芳基取代之吡啶及使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW112108367A TWI849782B (zh) 2016-06-03 2017-06-03 經雜芳基取代之吡啶及使用方法
TW110149319A TWI797926B (zh) 2016-06-03 2017-06-03 經雜芳基取代之吡啶及使用方法
TW113122971A TW202515560A (zh) 2016-06-03 2017-06-03 經雜芳基取代之吡啶及使用方法

Country Status (35)

Country Link
US (2) US10138227B2 (enExample)
EP (1) EP3464282B1 (enExample)
JP (3) JP6968094B2 (enExample)
KR (2) KR102719916B1 (enExample)
CN (2) CN114671864B (enExample)
AR (2) AR108672A1 (enExample)
AU (3) AU2017273215B2 (enExample)
CA (1) CA3022216A1 (enExample)
CL (1) CL2018003323A1 (enExample)
CO (1) CO2018012171A2 (enExample)
CR (1) CR20180547A (enExample)
CY (1) CY1124031T1 (enExample)
DK (1) DK3464282T3 (enExample)
DO (1) DOP2018000257A (enExample)
EC (1) ECSP18094790A (enExample)
ES (1) ES2806873T3 (enExample)
HR (1) HRP20201068T1 (enExample)
HU (1) HUE050248T2 (enExample)
IL (3) IL303196B2 (enExample)
LT (1) LT3464282T (enExample)
MX (2) MX385054B (enExample)
MY (1) MY199604A (enExample)
PE (1) PE20190511A1 (enExample)
PH (1) PH12018502534B1 (enExample)
PL (1) PL3464282T3 (enExample)
PT (1) PT3464282T (enExample)
RS (1) RS60574B1 (enExample)
RU (2) RU2021127810A (enExample)
SG (1) SG11201808842VA (enExample)
SI (1) SI3464282T1 (enExample)
SM (1) SMT202000394T1 (enExample)
TW (4) TWI752961B (enExample)
UY (2) UY37272A (enExample)
WO (1) WO2017208115A1 (enExample)
ZA (1) ZA201808423B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100921397B1 (ko) * 2009-02-09 2009-10-14 (주)오엠티 인쇄회로기판의 세척장비 및 이를 이용한 세척방법
PT3203840T (pt) 2014-10-06 2020-10-27 Vertex Pharma Moduladores do regulador da condutância transmembranar da fibrose quística
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Ｃｆｔｒ調節劑之結晶形式及組合物
MA51039A (fr) 2017-12-08 2020-10-14 Vertex Pharma Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
SI3752510T1 (sl) 2018-02-15 2023-03-31 Vertex Pharmaceuticals Incorporated Makrocikli kot modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki iz le-teh, njihova uporaba pri zdravljenju cistične fibroze in postopek za njihovo proizvodnjo
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IT201900000687A1 (it) * 2019-01-16 2020-07-16 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
AR118555A1 (es) 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2021011327A1 (en) 2019-07-12 2021-01-21 Orphomed, Inc. Compound for treating cystic fibrosis
SI4013741T1 (sl) 2019-08-14 2024-06-28 Vertex Pharmaceuticals Incorporated Postopek za izdelavo cftr-modulatorjev
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CA3150162A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
IL292966A (en) * 2019-11-12 2022-07-01 Genzyme Corp Heteroarylaminosulfonamides with 5 positions and methods of using them
US20230277550A1 (en) 2020-08-20 2023-09-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for Treating Respiratory Diseases Characterized by Mucus Hypersecretion
EP4259139A1 (en) 2020-12-10 2023-10-18 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
EP4274828A1 (en) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
KR20240041946A (ko) 2021-08-19 2024-04-01 신젠타 크롭 프로텍션 아게 디아미드 저항성 해충을 방제하는 방법 및 그를 위한 화합물
KR20250084132A (ko) 2022-09-15 2025-06-10 이도르시아 파마슈티컬스 리미티드 마크로시클릭 cftr 조절제
WO2024056791A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
CN116813569B (zh) * 2023-07-10 2024-07-02 衡阳市中心医院 一种抗癌药中间体的制备方法和抗癌药的制备方法
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI351949B (en) * 2007-04-02 2011-11-11 Inst Oneworld Health Cftr inhibitor compounds and uses thereof
WO2013038386A1 (en) * 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
TWI465449B (zh) * 2008-10-23 2014-12-21 Vertex Pharma 囊腫性纖維化跨膜傳導調節因子之調控因子
TWI515190B (zh) * 2010-03-19 2016-01-01 諾華公司 用於治療囊性纖維化（ｃｆ）之吡啶及吡嗪衍生物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561560A1 (en) * 2004-03-30 2005-10-13 The Regents Of The University Of California Hydrazide-containing cftr inhibitor compounds and uses thereof
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
NZ581419A (en) 2007-05-25 2012-05-25 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
NZ586271A (en) 2007-12-13 2012-08-31 Vertex Pharma Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
US8436014B2 (en) 2008-10-23 2013-05-07 Vertex Pharmaceutical Incorporated Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide
WO2010078103A1 (en) 2008-12-30 2010-07-08 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2011008931A2 (en) * 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
BR112013007907A2 (pt) 2010-10-08 2016-06-14 N30 Pharmaceuticals Inc novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase
WO2012154880A1 (en) * 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013043720A1 (en) 2011-09-20 2013-03-28 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
US9382254B2 (en) 2013-05-07 2016-07-05 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
DK3030568T3 (en) 2013-08-08 2019-01-07 Galapagos Nv THIENO [2,3-C] PYRANES AS CFTR MODULATORS
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
AU2015339196A1 (en) 2014-10-31 2017-05-11 Abbvie S.A.R.L. Substituted tetrahydropyrans and method of use
JP6676646B2 (ja) 2014-10-31 2020-04-08 アッヴィ・エス・ア・エール・エル 置換クロマンおよび使用方法
US10196384B2 (en) * 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
BR112017026132A2 (pt) * 2015-06-02 2018-08-28 AbbVie S.à.r.l. piridinas substituídas e métodos de uso
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
CN108431002A (zh) 2015-10-09 2018-08-21 艾伯维公司 取代的吡唑并[3，4-b]吡啶-6-甲酸及其用途
PT3359541T (pt) 2015-10-09 2020-11-11 Galapagos Nv Pirazol[3,4-b]piridin-6-carboxamidas n-sulfoniladas e método de utilização
BR112018072047A2 (pt) 2016-04-26 2019-02-12 AbbVie S.à.r.l. moduladores da proteína reguladora de condutância transmembranar de fibrose cística
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI351949B (en) * 2007-04-02 2011-11-11 Inst Oneworld Health Cftr inhibitor compounds and uses thereof
TWI465449B (zh) * 2008-10-23 2014-12-21 Vertex Pharma 囊腫性纖維化跨膜傳導調節因子之調控因子
TWI515190B (zh) * 2010-03-19 2016-01-01 諾華公司 用於治療囊性纖維化（ｃｆ）之吡啶及吡嗪衍生物
WO2013038386A1 (en) * 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis

Also Published As

Publication number Publication date
CR20180547A (es) 2019-10-30
KR20190015215A (ko) 2019-02-13
PT3464282T (pt) 2020-07-17
CA3022216A1 (en) 2017-12-07
EP3464282B1 (en) 2020-04-22
US10138227B2 (en) 2018-11-27
TW202214614A (zh) 2022-04-16
CY1124031T1 (el) 2022-03-24
KR20220162806A (ko) 2022-12-08
JP6968094B2 (ja) 2021-11-17
LT3464282T (lt) 2020-09-10
UY37272A (es) 2018-01-02
CO2018012171A2 (es) 2018-11-30
AU2017273215B2 (en) 2021-09-09
IL288243A (en) 2022-01-01
ES2806873T3 (es) 2021-02-18
IL288243B2 (en) 2023-11-01
JP2019517455A (ja) 2019-06-24
TW201802085A (zh) 2018-01-16
TW202329959A (zh) 2023-08-01
NZ747222A (en) 2025-06-27
RS60574B1 (sr) 2020-08-31
RU2756743C2 (ru) 2021-10-05
MX2018014758A (es) 2019-04-29
AR108672A1 (es) 2018-09-12
AU2024202468A1 (en) 2024-05-02
JP7622122B2 (ja) 2025-01-27
KR102719916B1 (ko) 2024-10-23
US10604515B2 (en) 2020-03-31
PE20190511A1 (es) 2019-04-10
SMT202000394T1 (it) 2020-09-10
CN114671864A (zh) 2022-06-28
AU2017273215A1 (en) 2018-10-25
TWI849782B (zh) 2024-07-21
UY40612A (es) 2024-02-15
AR124916A2 (es) 2023-05-17
BR112018074815A2 (pt) 2019-03-19
IL303196B2 (en) 2025-04-01
AU2021282409A1 (en) 2021-12-23
IL303196B1 (en) 2024-12-01
PL3464282T3 (pl) 2020-12-14
KR102469995B1 (ko) 2022-11-24
ECSP18094790A (es) 2019-01-31
IL288243B1 (en) 2023-07-01
TWI797926B (zh) 2023-04-01
CN114671864B (zh) 2025-04-08
EP3464282A1 (en) 2019-04-10
CL2018003323A1 (es) 2019-03-22
SI3464282T1 (sl) 2020-12-31
RU2018138707A3 (enExample) 2020-08-24
SG11201808842VA (en) 2018-11-29
ZA201808423B (en) 2019-08-28
JP7392211B2 (ja) 2023-12-06
IL262415B (en) 2021-12-01
US20170349576A1 (en) 2017-12-07
DOP2018000257A (es) 2018-12-31
RU2021127810A (ru) 2021-10-25
JP2022009448A (ja) 2022-01-14
NZ788542A (en) 2025-06-27
MX385054B (es) 2025-03-14
WO2017208115A1 (en) 2017-12-07
HUE050248T2 (hu) 2020-12-28
CN109311864B (zh) 2022-05-10
CN109311864A (zh) 2019-02-05
MY199604A (en) 2023-11-08
DK3464282T3 (da) 2020-07-27
IL303196A (en) 2023-07-01
MX2021009322A (es) 2021-09-08
IL262415A (en) 2018-12-31
AU2021282409B2 (en) 2024-01-18
HRP20201068T1 (hr) 2020-11-13
PH12018502534B1 (en) 2020-09-23
PH12018502534A1 (en) 2019-10-21
RU2018138707A (ru) 2020-07-14
JP2023172889A (ja) 2023-12-06
TW202515560A (zh) 2025-04-16
US20190055229A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
TWI752961B (zh) 經雜芳基取代之吡啶及使用方法
US10047051B2 (en) Substituted pyridines and method of use
CN103429585B (zh) 作为白细胞介素-1受体相关激酶抑制剂的吲唑基三唑衍生物
US20190135827A1 (en) Substituted Tricyclics and Method of Use
HK40006841A (en) Heteroaryl substituted pyridines and methods of use
HK40006841B (en) Heteroaryl substituted pyridines and methods of use
BR122024019066A2 (pt) Composto de piridina substituída com heteroarila, composições farmacêuticas que compreendem o mesmo e usos do mesmo para tratar fibrose cística
BR112018074815B1 (pt) Composto de piridina substituída com heteroarila
BR122024019066B1 (pt) Composto de piridina substituída com heteroarila, composições farmacêuticas que compreendem o mesmo e usos do mesmo para tratar fibrose cística